Acutaas Chemicals Limited (NSE:ACUTAAS)

Market Cap	152.48B
Revenue (ttm)	12.34B +33.7%
Net Income	2.87B +136.4%
EPS	34.76 +159.1%
Shares Out	81.87M
PE Ratio	53.58
Forward PE	45.54
Dividend	1.50 (0.09%)
Ex-Dividend Date	Sep 18, 2025

Volume	655,951
Average Volume	352,687
Open	1,910.00
Previous Close	1,862.40
Day's Range	1,885.10 - 1,946.10
52-Week Range	976.55 - 1,945.10
Beta	-0.04
RSI	70.11
Earnings Date	Jan 28, 2026

About Acutaas Chemicals

Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson’s, antidepressant, and anticoagulant applications. It also provides specialty chemicals for use in battery chemicals, personal care, agrochemicals, coatings, electronics, and industrial processes; photoresist...

• Industry: Specialty Chemicals
• Sector: Materials
• Founded: 2004
• Employees: 879
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ACUTAAS

Financial Performance

In fiscal year 2025, Acutaas Chemicals's revenue was 10.07 billion, an increase of 40.34% compared to the previous year's 7.17 billion. Earnings were 1.59 billion, an increase of 271.06%.